Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ERIS

ERIS

HealthcarePharmaceuticals & Biotechnology₹18587 cr market cap
₹1329.00 ▼ -0.61% today As of 19 Nov 2026
52-week low ₹1095.5052-week high ₹1701.30

-21.4% from the 52-week high · +22.1% above the low

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

The short version. ERIS reported revenue of ₹892 crore for Sep 2026, up 12.6% from a year earlier. Net profit was ₹184 crore (up 53.3% year on year). Return on equity was 15.9% in Mar 2026. Promoter holding was 54.74% in Sep 2026, down 0.12 points over 8 quarters.

1 · The price

How has the stock traded?

ERIS trades 21.4% below its 52-week high and 22.1% above its 52-week low.

Change over period: —

1M+19.3%
3M-0.8%
6M-8.3%
1Y-15.1%

2 · The business

Is it growing?

Sales, year on year+12.6%

Sep 2026 revenue of ₹892 cr.

Profit, year on year+53.3%

Sep 2026 net profit of ₹184 cr.

Net margin20.6%

5.4 pts higher than a year earlier.

3-year growth17.5% profit

Revenue compounded at 22.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue892873757807792773705727
Net profit1841422821001201189484
Net margin %20.616.337.212.315.215.313.311.5
EPS (₹)13.2510.2820.337.328.828.666.896.14

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue3129289420091685134712121074982
Net profit620352392382406355297291
Net margin %19.812.219.522.730.129.327.629.6
EPS (₹)44.7225.8428.8228.129.8826.1621.8421.15

3 · The quality

How well does it turn capital into profit?

Return on equity was 15.9% in Mar 2026; debt to equity is 0.59.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %15.912.315.217.4
Return on capital %15.712.711.413.4
EBITDA margin %35.435.634.432.3
Net margin %19.812.119.322.5

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR22.8%20.8%
Profit CAGR17.5%11.8%
Debt to equity0.59
Interest cover4.3x
Current ratio0.74
P/E ratio26.3

4 · The owners

Who holds it, and are they adding?

Promoter holding54.74%

Down 0.12 pts over 8 quarters.

Foreign institutions5.74%

Down 2.61 pts over 8 quarters.

Domestic institutions20.2%

Up 2.14 pts over 8 quarters.

Mutual fund schemes60

+12 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter54.8654.8554.8354.8554.8553.9254.1454.74-0.12
FII8.358.438.47.216.856.395.755.74-2.61
DII18.0618.0718.1719.3620.3220.3520.7220.2+2.14
Public18.7218.6618.5918.5717.9919.3319.419.32+0.6

Mutual fund holdings · Oct 2026

60 schemes hold this stock

48 the month before.

  • Motilal Oswal Innovation Opportunities Fund3.15% of NAV
  • Bank of India Consumption Fund2.59% of NAV
  • Bandhan Healthcare Fund2.49% of NAV
  • Mirae Asset Healthcare Fund2.27% of NAV
  • Franklin India Small Cap Fund2.08% of NAV
  • Bank of India Large & Mid Cap Fund2.01% of NAV
  • Bank Of India Multi Cap FUND1.93% of NAV
  • HDFC Small Cap Fund1.92% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ERIS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ERIS

What is the ERIS share price?

ERIS (ERIS) last closed at ₹1,329.00, down 0.61% on the day. Its 52-week range is ₹1,095.50 to ₹1,701.30.

What is the market cap of ERIS?

ERIS has a market capitalisation of about ₹18,587 crore. Its price-to-earnings ratio is 26.3.

How are ERIS's latest results?

ERIS reported revenue of ₹892 crore for Sep 2026, up 12.6% from a year earlier. Net profit was ₹184 crore (up 53.3% year on year). Return on equity was 15.9% in Mar 2026. Promoter holding was 54.74% in Sep 2026, down 0.12 points over 8 quarters.

Who owns ERIS?

As of Sep 2026, shareholding was: Promoter 54.74%, FII 5.74%, DII 20.2%, Public 19.32%.

How many mutual funds hold ERIS?

60 mutual fund schemes held ERIS in October 2026. That compares with 48 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 29 May 2026 · Interim Dividend - Rs. 7.21
  • 13 Feb 2025 · Interim Dividend - Rs. 7.35
  • 11 Aug 2022 · Interim Dividend - Rs. 7.35
  • 05 Aug 2021 · Interim Dividend - Rs. 6.01
  • 13 Aug 2020 · Interim Dividend - Rs. 5.5
  • 19 Mar 2020 · Interim Dividend - Rs. 2.87

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.